Disease-modifying therapies in Alzheimer's disease**EDITOR'S NOTE: The Journal intended to include this article in the January 2008 supplement, "Leon Thal Symposium on Prevention of Dementia."

Alzheimer's and Dementia

Volumn 4, Issue 2, 2008, Pages 65-79

  Salloway, Stephen ^a   Mintzer, Jacobo ^b   Weiner, Myron F ^c   Cummings, Jeffrey L ^d  

^a BROWN UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Disease modification; Neuroprotection

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIARRHYTHMIC AGENT; ARUNDIC ACID; ASCORBIC ACID; ATORVASTATIN; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BMS 299897; CLIOQUINOL; DONEPEZIL; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KMI 429; MEMANTINE; MUSCARINIC M1 RECEPTOR AGONIST; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NERAMEXANE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SELEGILINE; SIMVASTATIN; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCITOTOXICITY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFLAMMATION; NAUSEA AND VOMITING; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATION; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; VACCINATION;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 40749160944     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.001     Document Type: Review

References (172)

1. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
2. Ernst R.L., and Hay J.W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 84 (1994) 1261-1264
3. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
4. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
5. McLean C., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (1999) 860-866
6. Selkoe D.J. Presenilins, beta-amyloid precursor protein and the molecular basis of Alzheimer's disease. Clin Neurosci Res 1 (2001) 91-103
7. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
8. Cummings J.L. Drug therapy: Alzheimer's disease. N Engl J Med 351 (2004) 56-67
9. Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.M., Kalback W., Anthony J., et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41 (2002) 11080-11090
10. Cummings J.L. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trial. Alzheimer's & Dementia 2 (2006) 263-271
11. Bay E. Aphasia and nonverbal disorders of language. Brain 85 (1962) 411
12. Mani R.B. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 23 (2004) 305-314
13. Vellas B., Andrieu S., Sampaio C., and Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 6 (2007) 56-62
14. Sampaio C. Alzheimer disease: disease modifying trials; where are we? where do we need to go? a reflective paper. J Nutr Health Aging 10 (2006) 113-115
15. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
16. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24 (2004) 105-113
17. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
18. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
19. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
20. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
21. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
22. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
23. Albert M.L., Reches A., and Silverberg R. Associative visual agnosia without alexia. Neurology 25 (1975) 322
24. Dodel R.C., Du Y., Depboylu C., Hampel H., Frölich L., Haag A., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1472-1474
25. Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4 (2001) 231-232
26. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10 (2001) 1317-1324
27. Asai M., Hattori C., Iwata N., Saido T.C., Sasagawa N., Szabó B., et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96 (2006) 533-540
28. Jacobsen J.S., Reinhart P., and Pangalos M.N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2 (2005) 612-626
29. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B., et al. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305 (2003) 864-871
30. El Mouedden M., Vandermeeren M., Meert T., and Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des 12 (2006) 671-676
31. May P.C., Yang Z., Li W., Hyslop P.A., Siemers E., Boggs L.N., et al. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 25 Suppl 25 (2004) S65
32. Barten D.M., Guss V.L., Cosa J.A., Loo A., Hansel S.B., Zheng M., et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 312 (2005) 635-643
33. Comery T.A., Marton R.L., Aschmies S., Atchison K.P., Diamantidis G., Gong X., et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25 (2005) 8898-8902
34. Siemers E.R., Quinn J.F., Kaye J., Farlow M.R., Porsteinsson A., Tariot P., et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66 (2006) 602-604
35. Micchelli C.A., Esler W.P., Kimberly W.T., Jack C., Berezovska O., Kornilova A., et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. Faseb J 17 (2003) 79-81
36. Yang Q., Bermingham N.A., Finegold M.J., and Zoghbi H.Y. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294 (2001) 2155-2158
37. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
38. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
39. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
40. Morihara T., Chu T., Ubeda O., Beech W., and Cole G.M. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 83 (2002) 1009-1012
41. O'Donnell B.F., Drachman D.A., Barnes H.J., Peterson K.E., Swearer J.M., and Lew R.A. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 5 (1992) 45-52
42. Mintzer J.E., Wilcock G.K., Black S.E., Zavitz K.H., and Hendrix S.B. MPC-7869, a selective Abeta42-lowering agent, delays time to clinically significant psychiatric adverse events in Alzheimer's disease. analysis from a 12-month phase 2 trial. Presented as a poster exhibit at the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain (2006)
43. Gervais F., Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28 (2007) 537-547
44. th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland (2006)
45. Aisen P.S., Saumier D., Briand R., Laurin J., Gervais F., Tremblay P., et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67 (2006) 1757-1763
46. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60 (2006) 668-676
47. Sadowski M.J., Pankiewicz J., Scholtzova H., Mehta P.D., Prelli F., Quartermain D., et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A 103 (2006) 18787-18792
48. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
49. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 (2002) 223-227
50. 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98 (2001) 5856-5861
51. Simons M., Schwärzler F., Lütjohann D., von Bergmann K., Beyreuther K., Dichgans J., et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52 (2002) 346-350
52. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005) 753-757
53. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
54. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., et al. Do statins reduce risk of incident dementia and Alzheimer disease?. the Cache County Study. Arch Gen Psychiatry 62 (2005) 217-224
55. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26 Suppl 1 (2005) 65-69
56. Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17 (2004) 500-506
57. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199 (2006) 265-273
58. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13 (2005) 950-958
59. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6 (2006) 246-254
60. Geldmacher D.S., Frolich L., Doody R.S., Erkinjuntti T., Vellas B., Jones R.W., et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 10 (2006) 417-429
61. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20 (2006) 298-301
62. Cuajungco M.P., Frederickson C.J., and Bush A.I. Amyloid-beta metal interaction and metal chelation. Subcell Biochem 38 (2005) 235-254
63. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
64. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
65. Dedeoglu A., Cormier K., Payton S., Tseitlin K.A., Kremsky J.N., Lai L., et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 39 (2004) 1641-1649
66. Lee J.Y., Friedman J.E., Angel I., Kozak A., and Koh J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25 (2004) 1315-1321
67. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M.B., Weinreb O., et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97 (2006) 527-536
68. Fisher A., Pittel Z., Haring R., Bar-Ner N., Kliger-Spatz M., Natan N., et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 20 (2003) 349-356
69. Fisher A., Brandeis R., Bar-Ner R.H., Kliger-Spatz M., Natan N., Sonego H., et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 19 (2002) 145-153
70. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49 (2006) 671-682
71. Hock C., Maddalena A., Raschig A., Müller-Spahn F., Eschweiler G., Hager K., et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10 (2003) 1-6
72. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54 (1997) 465-473
73. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9 (2003) 907-913
74. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23 (2003) 29-33
75. Park J.H., Gimbel D.A., GrandPre T., Lee J.K., Kim J.E., Li W., et al. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J Neurosci 26 (2006) 1386-1395
76. Park J.H., Widi G.A., Gimbel D.A., Harel N.Y., Lee D.H., and Strittmatter S.M. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. J Neurosci 26 (2006) 13279-13286
77. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. Faseb J 18 (2004) 323-325
78. Fillenbaum G.G., Kuchibhatla M.N., Hanlon J.T., Artz M.B., Pieper C.F., Schmader K.E., et al. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother 39 (2005) 2009-2014
79. Maxwell C.J., Hicks M.S., Hogan D.B., Basran J., and Ebly E.M. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 20 (2005) 45-51
80. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61 (2004) 82-88
81. Devanand D.P., Jacobs D.M., Tang M.X., Del Castillo-Castaneda C., Sano M., Marder K., et al. The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry 54 (1997) 257-263
82. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
83. Frank B., and Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 17 (2005) 269-286
84. Cole G.M., Yang F., Lim G.P., Cummings J., Masterman D., and Frautschy S. A rational for curcuminoids for the prevention or treatment of Alzheimer's disease. Curr Med Chem 3 (2003) 15-25
85. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2 (2005) 131-136
86. Asano T., Mori T., Shimoda T., Shinagawa R., Satoh S., Yada N., et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 4 (2005) 127-142
87. Kato H., Kurosaki R., Oki C., and Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res 1030 (2004) 66-73
88. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
89. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., and Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55 (1998) 1449-1455
90. McCaddon A., Davies G., Hudson P., Tandy S., and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13 (1998) 235-239
91. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346 (2002) 476-483
92. Kruman I.I., Kumaravel T.S., Lohani A., Pedersen W.A., Cutler R.G., Kruman Y., et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22 (2002) 1752-1762
93. Kamath A.F., Chauhan A.K., Kisucka J., Dole V.S., Loscalzo J., Handy D.E., et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 107 (2006) 591-593
94. Finch C.E., Longo V., Miyao A., Morgan T.E., Rozovsky I., Soong Y., et al. Inflammation in Alzheimer's disease. In: Chesselet M.-F. (Ed). Molecular mechanisms of neurodegenerative diseases (2001), Human Press, Totowa, NJ 87-110
95. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54 (2000) 588-593
96. Scharf S., Mander A., Ugoni A., Vajda F., and Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1999) 197-201
97. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
98. Aisen P.S., Schmeidler J., and Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58 (2002) 1050-1054
99. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines G.R., Yuen E., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
100. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 12 (2000) 2735-2745
101. Amadoro G., Ciotti M.T., Costanzi M., Cestari V., Calissano P., and Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A 103 (2006) 2892-2897
102. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
103. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
104. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
105. Wenk G.L., Baker L.M., Stoehr J.D., Hauss-Wegrzyniak B., and Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol 347 (1998) 183-187
106. Bannerman D.M., Deacon R.M., Brady S., Bruce A., Sprengel R., Seeburg P.H., et al. A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav Neurosci 118 (2004) 643-647
107. Hampson R.E., Rogers G., Lynch G., and Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18 (1998) 2740-2747
108. Quirk J.C., and Nisenbaum E.S. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8 (2002) 255-282
109. Dicou E., Rangon C.M., Guimiot F., Spedding M., and Gressens P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res 970 (2003) 221-225
110. Buccafusco J.J., Weiser T., Winter K., Klinder K., and Terry A.V. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology 46 (2004) 10-22
111. Porrino L.J., Daunais J.B., Rogers G.A., Hampson R.E., and Deadwyler S.A. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 3 (2005) e299
112. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10 (2002) 24-35
113. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4 (1994) 1077-1086
114. Lovestone S., Davis D., Webster M.T., Kaech S., Brion J.P., Matus A., et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 45 (1999) 995-1003
115. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005) 6990-6995
116. Phiel C.J., Wilson C.A., Lee V.M., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435-439
117. Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., Lu M., et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100 (2003) 10032-10037
118. Maier J.K., Lahoua Z., Gendron N.H., Fetni R., Johnston A., Davoodi J., et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J Neurosci 22 (2002) 2035-2043
119. Rohn T.T., Head E., Nesse W.H., Cotman C.W., and Cribbs D.H. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 8 (2001) 1006-1016
120. Gastard M.C., Troncoso J.C., and Koliatsos V.E. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 54 (2003) 393-398
121. Kang H.J., Yoon W.J., Moon G.J., Kim D.Y., Sohn S., Kwon H.J., et al. Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol Dis 18 (2005) 450-458
122. Abrahamson E.E., Ikonomovic M.D., Ciallella J.R., Hope C.E., Paljug W.R., Isanski B.A., et al. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol 197 (2006) 437-450
123. Chen Y.H., Zhang Y.H., Zhang H.J., Liu D.Z., Gu M., Li J.Y., et al. Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem 49 (2006) 1613-1623
124. Saura J., Luue J.M., Cesura A.M., Da Prada M., Chan-Palay V., Huber G., et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62 (1994) 15-30
125. Kennedy B.P., Ziegler M.G., Alford M., Hansen L.A., Thal L.J., and Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J Neural Transm 110 (2003) 789-801
126. Youdim M.B., Bar Am O., Yogev-Falach M., Weinrab O., Maruyama W., Naoi M., et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79 (2005) 172-179
127. Hellstrom-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 19 (2004) 2703-2710
128. Levin E.D. Nicotinic receptor subtypes and cognitive function. J Neurobiol 53 (2002) 633-640
129. Lenzken S.C., Lanni C., Govoni S., Lucchelli A., Schettini G., and Racchi M. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 165 (2007) 138-145
130. Gatto G.J., Bohme G.A., Caldwell W.S., Letchworth S.R., Traina V.M., Obinu M.C., et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10 (2004) 147-166
131. Lopez O.L., Becker J.T., Wisniewski S., Saxton J., Kaufer D.I., and DeKosky S.T. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002) 310-314
132. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160 (2003) 2003-2011
133. Francis P.T., Nordberg A., and Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 26 (2005) 104-111
134. Mori E., Hashimoto M., Krishnan K.R., and Doraiswamy P.M. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?. Alzheimer Dis Assoc Disord 20 (2006) S19-S26
135. Racchi M., Mazzucchelli M., Porrello E., Lanni C., and Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50 (2004) 441-451
136. Sabbagh M.N., Farlow M.R., Relkin N., and Beach T.G. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. Alzheimer's & Dementia 2 (2006) 118-125
137. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006) S12-S18
138. Rogers S.L., Doody R.S., Pratt R.D., and Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10 (2000) 195-203
139. Huang E.J., and Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24 (2001) 677-736
140. Sofroniew M.V., Howe C.L., and Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24 (2001) 1217-1281
141. Chao M.V., Rajagopal R., and Lee F.S. Neurotrophin signalling in health and disease. Clin Sci (Lond) 110 (2006) 167-173
142. Williams L.R., Varon S., Peterson G.M., Wictorin K., Fischer W., Bjorklund A., et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83 (1986) 9231-9235
143. Chen K.S., Nishimura M.C., Armanini M.P., Crowley C., Spencer S.D., and Phillips H.S. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 17 (1997) 7288-7296
144. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 (2005) 551-555
145. Ruether E., Husmann R., Kinzler E., Diabl E., Klingler D., Spatt J., et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 16 (2001) 253-263
146. Fournier J., Steinberg R., Gauthier T., Keane P.E., Guzzi U., Coude F.X., et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55 (1993) 629-641
147. Labie C., Lafon C., Marmouget C., Saubusse P., Fournier J., Keane P.E., et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol 127 (1999) 139-144
148. Duong F.H., Warter J.M., Poindron P., and Passilly P. Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons. Br J Pharmacol 128 (1999) 1385-1392
149. Fournier J., Keane P.E., Ferrara P., and Soubrie P. SR57746A: An orally active non-peptide compound with neurotrophic and neuroprotective effects. CNS Drug Reviews 3 (1997) 148-167
150. Lemaire L., Fournier J., Ponthus C., Le Fur Y., Confort-Gouny S., Vion-Dury J., et al. Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Invest Radiol 37 (2002) 321-327
151. Rockenstein E., Adame A., Mante M., Moessler H., Windisch M., and Masliah E. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110 (2003) 1313-1327
152. Panisset M., Gauthier S., Moessler H., and Windisch M. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 109 (2002) 1089-1104
153. Alvarez X.A., Cacabelos R., Laredo M., Couceiro V., Sampredo C., Varela M., et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13 (2006) 43-54
154. Smith D.E., Roberts J., Gage F.H., and Tuszynski M.H. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci U S A 96 (1999) 10893-10898
155. Tuszynski M.H., Roberts J., Senut M.C., and Gage F.H. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. U HS. Gene Ther 3 (1996) 305-314
156. Gandy S., Martins R.N., and Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 17 (2003) 259-266
157. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5 (2004) 677-685
158. Wolfe M.S. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 1 (2002) 859-866
159. Saver J.L., and Kalafut M. Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiology 20 (2001) 57-64
160. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathias C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5 (2002) 452-457
161. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
162. Wilcock D.M., Roiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1 (2004) 24
163. Ferris S.H., Aisen P.S., Cummings J., Galasko D., Salmon D.P., Schneider L., et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 20 Suppl 3 (2006) S109-S123
164. Jack C.R., Slomkowski M., Gracon S., Hoover T.M., Felmlee J.P., Stewart K., et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60 (2003) 253-260
165. Fox N.C., Cousens S., Scahill R., Harvey R.J., and Rossor M.N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease. Arch Neurol 57 (2000) 339-344
166. Schott J.M., Price S.L., Frost C., Whitwell J.L., Rossor M.N., and Fox N.C. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 65 (2005) 119-124
167. DeCarli C., Frisoni G.B., Clark C.M., Harvey D., Grundman M., Petersen R.C., et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64 (2007) 108-115
168. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
169. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
170. 2-isoprostane concentration in probable AD. Neurology 52 (1999) 562-565
171. alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48 (2000) 809-812
172. Yao Y., Clark C.M., Trojanowski J.Q., Lee V.M.-Y., and Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58 (2005) 623-626